medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2022, Number 1

<< Back Next >>

Biotecnol Apl 2022; 39 (1)

Novel contributions to the study of immunological effectors induced by the specific active immunotherapy CIGB-247

Sánchez RJ, Morera DY, Bequet RM, Hernández BF, Ayala ÁM, Gavilondo CJV, Martin BY, Selman-Housein BKH, de la Torre SAV, Pérez IM, Trimiño LL, Limonta FM

Language: English
References: 29
Page: 1501-1507
PDF size: 350.83 Kb.


ABSTRACT

The primary aim of this work is to study the immunological effectors induced in CIGB-247-vaccinated patients. These effectors include humoral and cellular components of the immune system. Also, the goal of the present investigation is to detect different immunoglobulin classes and subclasses and its specificity for VEGF relevant epitopes, and demonstrate the induction of VEGF-specific and cytotoxic CD8 T lymphocytes. This research has, as an additional objective, the presentation of the first preliminary pieces of evidence of the feasibility to combine CIGB-247 with other anti-cancer treatments. To investigate the vaccine-induced immunological effectors, ELISA and ELISPOT tests were used for monitoring the immune response elicited in cancer patients from the CENTAURO and CENTAURO-2 clinical trials and also those from the compassionate use program. Immunization with CIGB-247 elicited VEGF-specific IgM and IgA antibodies. Antibody response maturation was detected in some patients with long term overall survival, indicated by the subclass switching from IgG1 to IgG4. This antibody response blocked the interaction of VEGF with its receptors VEGFR2 and VEGFR1. This specific polyclonal antibody response inhibited the binding between VEGF and the monoclonal antibody bevacizumab, for that reason, it was directed to a relevant epitope on VEGF, implicated in the VEGF-induced proangiogenic activity. The vaccination contributed to normalizing platelet VEGF levels, and produced cytotoxic CD8 T lymphocytes. Some experimental evidence indicated the potential use of CIGB-247 in combination with chemotherapy. Conclusions: All these results allowed for the application of CIGB-247 in phase II clinical trials in combination with other cancer therapeutic treatments. This work received the Annual Award of the Cuban Academy of Sciences for the year 2020.


REFERENCES

  1. Morera Y, Bequet M, Ayala M, LamdánH, Agger EM, Andersen P, et al. Antitumoraleffect of active immunotherapy inC57BL/6 mice using a recombinant humanVEGF protein as antigen and three chemicallyunrelated adjuvants. Angiogenesis. 2008;11(4):381-93.

  2. Acevedo R, Fernández S, Zayas C,Acosta A, Sarmiento ME, Ferro VA, et al.Bacterial outer membrane vesicles andvaccine applications. Front Immunol.2014;5:121.

  3. Morera Y, Bequet M, Ayala M, VelazcoJC, Pérez PP, Alba JS, et al. Immunogenicityand some safety features of a VEGF-basedcancer therapeutic vaccine in rats, rabbitsand non-human primates. Vaccine.2010;28(19):3453-61.

  4. Bequet M, Morera Y, Ayala M, AncízarJ, Soria Y, Blanco A, et al. CIGB-247: aVEGF-based therapeutic vaccine that reducesexperimental and spontaneous lungmetastasis of C57Bl/6 and BALB/c mousetumors. Vaccine. 2012;30(10):1790-9.

  5. Gavilondo JV, Hernández F, Ayala M,de la Torre AV, de la Torre J, Morera Y, etal. Specific active immunotherapy with aVEGF vaccine in patients with advancedsolid tumors. results of the CENTAUROantigen dose escalation phase I clinicaltrial. Vaccine. 2014;32(19):2241-50.

  6. Sánchez Ramírez J, Morera Díaz Y,Bequet-Romero M, Hernández-Bernal F,Selman-Housein Bernal K-H, de la TorreSantos A, et al. Characteristics of thespecific humoral response in patients withadvanced solid tumors after active immunotherapywith a VEGF vaccine, at differentantigen doses and using two distinct adjuvants.BMC immunology. 2017;18(1):39.

  7. Morera Y, Sánchez J, Bequet-RomeroM, Selman-Housein KH, de la Torre A,Hernández-Bernal F, et al. Specific humoraland cellular immune responses in cancerpatients undergoing chronic immunizationwith a VEGF-based therapeutic vaccine.Vaccine. 2017;35(28):3582-90.

  8. Sánchez Ramírez J, Morera Díaz Y,Bequet-Romero M, Hernandez-Bernal F,Martin Bauta Y, Selman-Housein BernalKH, et al. Specific humoral response incancer patients treated with a VEGFspecificactive immunotherapy procedurewithin a compassionate use program. BMCimmunology. 2020;21(1):12.

  9. Zhang Z, Neiva KG, Lingen MW, EllisLM, Nor JE. VEGF-dependent tumor angiogenesisrequires inverse and reciprocalregulation of VEGFR1 and VEGFR2. Celldeath and differentiation. 2010;17(3):499-512.

  10. Voron T, Marcheteau E, Pernot S,Colussi O, Tartour E, Taieb J, et al. Controlof the immune response by pro-angiogenicfactors. Front Oncol. 2014;4:70.

  11. Cohen MH, Gootenberg J, Keegan P,Pazdur R. FDA drug approval summary:bevacizumab (Avastin) plus Carboplatinand Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamousnon-small cell lung cancer. Oncologist.2007;12(6):713-8.

  12. Cohen MH, Gootenberg J, Keegan P,Pazdur R. FDA drug approval summary:bevacizumab plus FOLFOX4 as second-linetreatment of colorectal cancer. Oncologist.2007;12(3):356-61.

  13. Cohen MH, Shen YL, Keegan P, PazdurR. FDA drug approval summary: bevacizumab(Avastin) as treatment of recurrentglioblastoma multiforme. Oncologist.2009;14(11):1131-8.

  14. Summers J, Cohen MH, KeeganP, Pazdur R. FDA drug approval summary:bevacizumab plus interferon foradvanced renal cell carcinoma. Oncologist.2010;15(1):104-11.

  15. Pujade-Lauraine E, Hilpert F, WeberB, Reuss A, Poveda A, Kristensen G, etal. Bevacizumab combined with chemotherapyfor platinum-resistant recurrentovarian cancer: The AURELIA open-labelrandomized phase III trial. J Clin Oncol.2014;32(13):1302-8.

  16. Wick W, Brandes AA, Gorlia T, BendszusM, Sahm F, Taal W, et al. EORTC 26101phase III trial exploring the combinationof bevacizumab and lomustine in patientswith first progression of a glioblastoma. JClin Oncol. 2016;34(15 suppl):2001.

  17. Higa GM, Abraham J. Biologicalmechanisms of bevacizumab-associatedadverse events. Expert review of anticancertherapy. 2009;9(7):999-1007.

  18. Sánchez Ramírez J, Morera Díaz Y,Musacchio Lasa A, Bequet-Romero M,Muñoz Pozo Y, Pérez Sánchez L, et al.Indirect and competitive enzyme-linkedimmunosorbent assays for monitoringthe humoral response against humanVEGF. J Immunoassay Immunochem.2016;37(6):636-58.

  19. Adams J, Carder PJ, Downey S, ForbesMA, MacLennan K, Allgar V, et al. Vascularendothelial growth factor (VEGF)in breast cancer: comparison of plasma,serum, and tissue VEGF and microvesseldensity and effects of tamoxifen. CancerRes. 2000;60(11):2898-905.

  20. Wen YM, Mu L, Shi Y. Immunoregulatoryfunctions of immune complexes invaccine and therapy. 2016;8(10):1120-33.

  21. de Jong JM, Schuurhuis DH, Ioan-Facsinay A, Welling MM, Camps MG,van der Voort EI, et al. Dendritic cells,but not macrophages or B cells, activatemajor histocompatibility complex classII-restricted CD4+ T cells upon immunecomplexuptake in vivo. Immunology.2006;119(4):499-506.

  22. den Haan JM, Bevan MJ. Constitutiveversus activation-dependent crosspresentationof immune complexes byCD8(+) and CD8(-) dendritic cells in vivo.J Exp Med. 2002;196(6):817-27.

  23. Shen L, van Egmond M, Siemasko K,Gao H, Wade T, Lang ML, et al. Presentationof ovalbumin internalized via theimmunoglobulin-A Fc receptor is enhancedthrough Fc receptor gamma-chain signaling.Blood. 2001;97(1):205-13.

  24. Shibuya A, Honda S. Molecular andfunctional characteristics of the Fcalpha/muR, a novel Fc receptor for IgM andIgA. Springer Seminars Immunopathol.2006;28(4):377-82.

  25. Tewari KS, Sill MW, Long HJ, PensonRT, Huang H, Ramondetta LM, et al.Improved Survival with Bevacizumab inAdvanced Cervical Cancer. New Engl JMed. 2014;370(8):734-43.

  26. Sánchez Ramírez J, Bequet-Romero M,Morera Díaz Y, Hernández-Bernal F, AyalaAvila M. Does VEGF-targeted active immunotherapyinduce complete abrogationof platelet VEGF levels? BMC Res Notes.2019;12(1):323.

  27. Karp JE, Gojo I, Pili R, Gocke CD,Greer J, Guo C, et al. Targeting vascularendothelial growth factor for relapsedand refractory adult acute myelogenousleukemias: therapy with sequential 1-betad-arabinofuranosylcytosine, mitoxantrone,and bevacizumab. Clin Cancer Res.2004;10(11):3577-85.

  28. Wentink MQ, Hackeng TM, TabruynSP, Puijk WC, Schwamborn K, AltschuhD, et al. Targeted vaccination against thebevacizumab binding site on VEGF using3D-structured peptides elicits efficientantitumor activity. Proc Natl Acad Sci USA.2016;113(44):12532-7.

  29. Goedegebuure RSA, Wentink MQ, vander Vliet HJ, Timmerman P, Griffioen AW,de Gruijl TD, et al. A phase I open-labelclinical trial evaluating the therapeutic vaccinehVEGF26-104/RFASE in patients withadvanced solid malignancies. Oncologist.2021;26(2):e218-29.




2020     |     www.medigraphic.com